Translational Research in Alzheimer's and Prion Diseases

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2017 Nov 25

PMID 29172000

Citations 5

Authors

Giuseppe Di Fede

Giorgio Giaccone

Mario Salmona

Fabrizio Tagliavini

Affiliations

Soon will be listed here.

Abstract

Translational neuroscience integrates the knowledge derived by basic neuroscience with the development of new diagnostic and therapeutic tools that may be applied to clinical practice in neurological diseases. This information can be used to improve clinical trial designs and outcomes that will accelerate drug development, and to discover novel biomarkers which can be efficiently employed to early recognize neurological disorders and provide information regarding the effects of drugs on the underlying disease biology. Alzheimer's disease (AD) and prion disease are two classes of neurodegenerative disorders characterized by incomplete knowledge of the molecular mechanisms underlying their occurrence and the lack of valid biomarkers and effective treatments. For these reasons, the design of therapies that prevent or delay the onset, slow the progression, or improve the symptoms associated to these disorders is urgently needed. During the last few decades, translational research provided a framework for advancing development of new diagnostic devices and promising disease-modifying therapies for patients with prion encephalopathies and AD. In this review, we provide present evidence of how supportive can be the translational approach to the study of dementias and show some results of our preclinical studies which have been translated to the clinical application following the 'bed-to-bench-and-back' research model.

Citing Articles

Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far?.

Miranda L, Oliveira A, Carvalho D, Souza G, Magalhaes J, Junior J Arq Neuropsiquiatr. 2022; 80(8):837-844.

PMID: 36252593 PMC: 9703894. DOI: 10.1055/s-0042-1755341.

A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer's disease.

Catania M, Colombo L, Sorrentino S, Cagnotto A, Lucchetti J, Barbagallo M Mol Psychiatry. 2022; 27(12):5227-5234.

PMID: 36028569 PMC: 9763104. DOI: 10.1038/s41380-022-01745-x.

Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review.

Altuna M, Ruiz I, Zelaya M, Mendioroz M Medicina (Kaunas). 2022; 58(4).

PMID: 35454316 PMC: 9030755. DOI: 10.3390/medicina58040473.

Gut Microbiota Disorder, Gut Epithelial and Blood-Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways.

Welcome M Neuromolecular Med. 2019; 21(3):205-226.

PMID: 31115795 DOI: 10.1007/s12017-019-08547-5.

Clinical and neuropathological phenotype associated with the novel V189I mutation in the prion protein gene.

Di Fede G, Catania M, Atzori C, Moda F, Pasquali C, Indaco A Acta Neuropathol Commun. 2019; 7(1):1.

PMID: 30606247 PMC: 6317215. DOI: 10.1186/s40478-018-0656-4.

References

van Duinen S, Castano E, Prelli F, BOTS G, LUYENDIJK W, Frangione B . Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease. Proc Natl Acad Sci U S A. 1987; 84(16):5991-4. PMC: 298989. DOI: 10.1073/pnas.84.16.5991. View

Di Fede G, Catania M, Maderna E, Morbin M, Moda F, Colombo L . Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. Sci Rep. 2016; 6:20949. PMC: 4750079. DOI: 10.1038/srep20949. View

Sy M, Gambetti P, Wong B . Human prion diseases. Med Clin North Am. 2002; 86(3):551-71, vi-vii. DOI: 10.1016/s0025-7125(02)00004-4. View

De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C . The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One. 2008; 3(3):e1888. PMC: 2268013. DOI: 10.1371/journal.pone.0001888. View

Cantu L, Colombo L, Stoilova T, Deme B, Inouye H, Booth R . The A2V mutation as a new tool for hindering Aβ aggregation: A neutron and x-ray diffraction study. Sci Rep. 2017; 7(1):5510. PMC: 5511251. DOI: 10.1038/s41598-017-05582-9. View

Koster T, Singh K, Zimmermann M, Gruys E . Emerging therapeutic agents for transmissible spongiform encephalopathies: a review. J Vet Pharmacol Ther. 2003; 26(5):315-26. DOI: 10.1046/j.1365-2885.2003.00525.x. View

Drew S, Masters C, Barnham K . Alzheimer's Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination. PLoS One. 2011; 5(12):e15875. PMC: 3012727. DOI: 10.1371/journal.pone.0015875. View

Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw J, Haik S . Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiol Aging. 2007; 29(12):1864-73. DOI: 10.1016/j.neurobiolaging.2007.04.026. View

Benilova I, Gallardo R, Ungureanu A, Castillo Cano V, Snellinx A, Ramakers M . The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. J Biol Chem. 2014; 289(45):30977-89. PMC: 4223304. DOI: 10.1074/jbc.M114.599027. View

10.

Aguzzi A, Nuvolone M, Zhu C . The immunobiology of prion diseases. Nat Rev Immunol. 2013; 13(12):888-902. DOI: 10.1038/nri3553. View

11.

Ghetti B, Dlouhy S, Giaccone G, Bugiani O, Frangione B, Farlow M . Gerstmann-Sträussler-Scheinker disease and the Indiana kindred. Brain Pathol. 1995; 5(1):61-75. DOI: 10.1111/j.1750-3639.1995.tb00578.x. View

12.

Ghetti B, Piccardo P, Spillantini M, Ichimiya Y, Porro M, Perini F . Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A. 1996; 93(2):744-8. PMC: 40125. DOI: 10.1073/pnas.93.2.744. View

13.

Zhang S, Wang Z, Cai F, Zhang M, Wu Y, Zhang J . BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis. J Neurosci. 2017; 37(29):6915-6925. PMC: 6705717. DOI: 10.1523/JNEUROSCI.0340-17.2017. View

14.

Giovagnoli A, Di Fede G, Aresi A, Reati F, Rossi G, Tagliavini F . Atypical frontotemporal dementia as a new clinical phenotype of Gerstmann-Straussler-Scheinker disease with the PrP-P102L mutation. Description of a previously unreported Italian family. Neurol Sci. 2008; 29(6):405-10. DOI: 10.1007/s10072-008-1025-z. View

15.

Piccardo P, Seiler C, Dlouhy S, Young K, Farlow M, Prelli F . Proteinase-K-resistant prion protein isoforms in Gerstmann-Sträussler-Scheinker disease (Indiana kindred). J Neuropathol Exp Neurol. 1996; 55(11):1157-63. DOI: 10.1097/00005072-199611000-00007. View

16.

Diomede L, Di Fede G, Romeo M, Bagnati R, Ghidoni R, Fiordaliso F . Expression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity. Neurobiol Dis. 2013; 62:521-32. PMC: 4068289. DOI: 10.1016/j.nbd.2013.10.024. View

17.

Bohm C, Chen F, Sevalle J, Qamar S, Dodd R, Li Y . Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways. Mol Cell Neurosci. 2015; 66(Pt A):3-11. PMC: 4503820. DOI: 10.1016/j.mcn.2015.02.016. View

18.

Rocchi A, Pellegrini S, Siciliano G, Murri L . Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull. 2003; 61(1):1-24. DOI: 10.1016/s0361-9230(03)00067-4. View

19.

Bugiani O, Giaccone G, Rossi G, Mangieri M, Capobianco R, Morbin M . Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch Neurol. 2010; 67(8):987-95. DOI: 10.1001/archneurol.2010.178. View

20.

Gambetti P, Cali I, Notari S, Kong Q, Zou W, Surewicz W . Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathol. 2010; 121(1):79-90. PMC: 3077936. DOI: 10.1007/s00401-010-0761-3. View